Health Care & Life Sciences » Biotechnology | Intellia Therapeutics Inc.

Intellia Therapeutics Inc. | Ownership

Companies that own Intellia Therapeutics Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
ARK Investment Management LLC
4,513,584
10.45%
910,608
4.59%
06/30/2018
SSgA Funds Management, Inc.
2,696,421
6.24%
1,154,809
0.01%
06/30/2018
Fidelity Management & Research Co.
2,466,290
5.71%
-108,700
0.01%
06/30/2018
BlackRock Fund Advisors
2,376,303
5.5%
739,731
0%
06/30/2018
The Vanguard Group, Inc.
2,301,116
5.33%
311,739
0%
06/30/2018
Morgan Stanley Investment Management, Inc.
1,716,912
3.97%
58,442
0.07%
06/30/2018
Fidelity (Canada) Asset Management ULC
1,111,395
2.57%
-57,003
0.05%
03/31/2018
OrbiMed Advisors LLC
876,000
2.02%
-237,000
0.28%
06/30/2018
Farallon Capital Management LLC
840,000
1.94%
190,000
0.17%
06/30/2018
Temasek Holdings Pte Ltd. (Investment Management)
790,527
1.83%
0
0.05%
06/30/2018

About Intellia Therapeutics

View Profile
Address
40 Erie Street
Cambridge Massachusetts 02139
United States
Employees -
Website http://www.intelliatx.com
Updated 07/08/2019
Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.